Inside-out neuropharmacology of nicotinic drugs.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and cellular pharmacology without primary clinical data
PubMed 25660637 · doi:10.1016/j.neuropharm.2015.01.022
What was done
This narrative review summarizes current mechanistic evidence on how nicotine and other nicotinic agonists act inside intracellular organelles to alter neuronal nicotinic acetylcholine receptor (AChR) processing, a concept termed "inside-out pharmacology."
What was found
The abstract reports no numerical data or effect sizes. It describes a mechanistic model wherein cell-permeable nicotinic ligands bind immature intracellular AChR oligomers, induce conformational changes, strengthen subunit interactions, promote maturation into stable pentamers, increase secretory pathway trafficking, and modulate endoplasmic reticulum stress and the unfolded protein response, ultimately resulting in receptor upregulation at the plasma membrane.
Why it matters
This framework distinguishes intracellular pharmacological chaperoning from classical cell-surface receptor activation, providing a mechanistic explanation for chronic nicotine-induced receptor upregulation.
Limits
The review provides theoretical and mechanistic synthesis rather than systematic review or meta-analysis. The abstract provides no quantitative data, and findings are based on cellular and bench models rather than human clinical outcomes.
Cited by
- supports Daily nicotine use causes the brain to upregulate and produce more nicotinic acetylcholine receptors.